Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux

This study has been completed.
Sponsor:
Information provided by:
University of California, Davis
ClinicalTrials.gov Identifier:
NCT00584259
First received: December 26, 2007
Last updated: July 12, 2010
Last verified: July 2010

December 26, 2007
July 12, 2010
May 2006
January 2010   (final data collection date for primary outcome measure)
coffee leads to reflux events [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00584259 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux
Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux

Investigation evaluating the effect of coffee on gastro-esophageal reflux disease.

Many patients with gastro-esophageal reflux disease (GERD) report that drinking coffee causes heartburn. The purpose of this study is to investigate the effects of coffee on gastro-esophageal acid reflux, and its relation to esophageal motility parameters in patients who are already scheduled to undergo 48 hour wireless pH testing as a result of having symptoms suggestive of GERD. The specific aims are to evaluate the effects of coffee on GERD during daily life and to elucidate the underlying pathogenic mechanism by which coffee induces reflux.

Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
GERD
Other: Coffee
3 cups of coffee over a 24 hour period
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
7
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • persons undergoing wireless pH testing for diagnosis and treatment of GERD

Exclusion Criteria:

  • those under the age of 18
  • pregnant and lactating women
  • those who do not meet the inclusion criteria
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00584259
200614348-2
No
Peter Belafsky, MD, Ph.D., University of California Davis
University of California, Davis
Not Provided
Principal Investigator: Peter Belafsky, MD, PhD University of California, Davis
University of California, Davis
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP